{"organizations": [], "uuid": "6d89247b9094d44235a622f9a769404b8159bf8a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/06/pr-newswire-andrew-s-boyer-joins-amneal-pharmaceuticals-as-executive-vice-president-commercial-operations.html", "country": "US", "domain_rank": 767, "title": "Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-06T15:30:00.000+02:00", "replies_count": 0, "uuid": "6d89247b9094d44235a622f9a769404b8159bf8a"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/06/pr-newswire-andrew-s-boyer-joins-amneal-pharmaceuticals-as-executive-vice-president-commercial-operations.html", "ord_in_thread": 0, "title": "Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations", "locations": [], "entities": {"persons": [{"name": "andrew s. boyer", "sentiment": "negative"}, {"name": "amneal", "sentiment": "none"}, {"name": "chintu patel", "sentiment": "none"}, {"name": "rob stewart", "sentiment": "none"}, {"name": "andy", "sentiment": "none"}, {"name": "chirag patel", "sentiment": "none"}, {"name": "boyer", "sentiment": "none"}], "locations": [{"name": "n.j.", "sentiment": "none"}, {"name": "bridgewater", "sentiment": "none"}, {"name": "amneal", "sentiment": "none"}], "organizations": [{"name": "impax laboratories", "sentiment": "negative"}, {"name": "amneal pharmaceuticals", "sentiment": "negative"}, {"name": "amneal pharmaceuticals llc", "sentiment": "negative"}, {"name": "amneal", "sentiment": "none"}, {"name": "amn", "sentiment": "none"}, {"name": "impax", "sentiment": "none"}, {"name": "teva pharmaceuticals, inc.", "sentiment": "none"}, {"name": "north america generics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BRIDGEWATER, N.J., Feb. 6, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that Andrew S. Boyer, 52, has joined Amneal as Executive Vice President, Commercial Operations and is expected to serve in the same capacity for the new combined company following the consummation of the combination with Impax. Mr. Boyer most recently served as President and CEO of North America Generics, Teva Pharmaceuticals, Inc.\n\"We are pleased that Andy has joined Amneal and will be leading our commercial organization,\" said Chirag Patel, Co-CEO and chairman, Amneal Pharmaceuticals. \"Andy is an accomplished executive with more than 20 years of pharmaceutical experience architecting commercial strategies designed to capitalize on changing customer needs and market opportunities. His addition further enhances our current leadership team as well as the proposed leadership team for the new Amneal.\"\nMr. Boyer will work closely with Chirag and Chintu Patel, Amneal's current Co-CEOs, and Rob Stewart, President of Amneal and the future CEO of the new Amneal, to further enhance its business in preparation for the pending combination with Impax, which is currently expected to occur in the first half of 2018.\nMr. Boyer commented, \"I am excited to join Amneal at this important time in the company's evolution and eventual combination with Impax. Amneal has an exceptional generics portfolio and is well regarded by customers for its quality, value and service. I look forward to working with my new colleagues to build upon that strong foundation and lead the combined organization's continued advancement as a generic pharmaceuticals leader.\"\nPrior to joining Teva, Mr. Boyer was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan plc (formerly, Actavis plc; formerly, Watson Pharmaceuticals, Inc.) since September of 2006. Mr. Boyer joined Allergan in 1998 as Associate Director of Marketing in Generics. Before joining Allergan, Mr. Boyer served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of Association for Accessible Medicines. Mr. Boyer received his bachelor's degree in Business Administration and Management from State University of New York at Albany.\nAbout Amneal\nAmneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in its operations in North America, Asia, and Europe, working together to bring high-quality, affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit www.amneal.com .\nAbout Impax\nImpax Laboratories, Inc. is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. For more information, please visit Impax's web site at: www.impaxlabs.com .\nAdditional Information and Where to Find It\nThis communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitation material in respect of the proposed transaction between Impax Laboratories, Inc. (\"Impax\") and Amneal Pharmaceuticals LLC (\"Amneal\") pursuant to the Business Combination Agreement dated as of October 17, 2017 by and among Impax, Amneal, Atlas Holdings, Inc. (\"Holdco\"), and K2 Merger Sub Corporation as amended by Amendment No. 1, dated November 21, 2017 and Amendment No. 2 dated December 16, 2017. In connection with the proposed transaction, Holdco filed a registration statement on Form S-4, containing a preliminary proxy statement/prospectus, with the Securities and Exchange Commission (\"SEC\") on November 21, 2017. A definitive proxy statement/prospectus will be delivered as required by applicable law after the registration statement on Form S-4 is declare effective by the SEC. This communication is not a substitute for the registration statement, definitive proxy statement/prospectus or any other documents that Impax or Holdco has filed or may file with the SEC or send to stockholders in connection with the proposed business combination. INVESTORS AND SECURITY HOLDERS OF IMPAX ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT/PROSPECTUS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.\nInvestors and security holders will be able to obtain copies of the registration statement, including the proxy statement/prospectus and other documents filed with the SEC (when available) free of charge at the SEC's website, http://www.sec.gov . Copies of the documents filed with the SEC by Impax or Holdco will be available free of charge on Impax's internet website at http://www.impaxlabs.com or by contacting Mark Donohue, Investor Relations and Corporate Communications at (215) 558-4526.\nForward-Looking Statements\nThis communication includes \"forward-looking statements\" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on our beliefs and assumptions. These forward-looking statements are identified by terms and phrases such as: anticipate, believe, intend, estimate, expect, continue, should, could, may, plan, project, predict, will, target, potential, forecast, and the negative thereof and similar expressions. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the potential timing or consummation of the proposed transaction or the anticipated benefits thereof, including, without limitation, future financial and operating results. Impax cautions readers that these and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that could cause actual results to differ materially from those indicated in any forward-looking statement include, but are not limited to: (i) the ability to obtain shareholder and regulatory approvals, or the possibility that they may delay the transaction or that such regulatory approval may result in the imposition of conditions that could cause the parties to abandon the transaction, (ii) the risk that a condition to effecting the transaction may not be satisfiedÍ¾ (iii) the ability of Impax and Amneal to integrate their businesses successfully and to achieve anticipated synergies, (iv) the possibility that other anticipated benefits of the proposed transaction will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of the new combined company's operations, and the anticipated tax treatment, (v) potential litigation relating to the proposed transaction that could be instituted against Impax, Amneal or their respective directors, (vi) possible disruptions from the proposed transaction that could harm Impax's and/or Amneal's business, including current plans and operations, (vii) the ability of Impax or Amneal to retain, attract and hire key personnel, (viii) potential adverse reactions or changes to relationships with clients, employees, suppliers or other parties resulting from the announcement or completion of the transaction, (ix) potential business uncertainty, including changes to existing business relationships, during the pendency of the business combination that could affect Impax's or Amneal's financial performance, (x) certain restrictions during the pendency of the transaction that may impact Impax's or Amneal's ability to pursue certain business opportunities or strategic transactions, (xi) continued availability of capital and financing and rating agency actions, (xii) legislative, regulatory and economic developments; (xiii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors; and (xiv) such other factors as are set forth in Impax's periodic public filings with the SEC, including but not limited to those described under the headings \"Risk Factors\" and \"Cautionary Statement Regarding Forward-Looking Information\" in Impax's Form 10-K for the fiscal year ended December 31, 2016, in the Form S-4 filed by Holdco and in Impax's other filings made with the SEC from time to time, which are available via the SEC's website at www.sec.gov . While the list of factors presented here is, and the list of factors to be presented in the proxy statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Impax's or Amneal's consolidated financial condition, results of operations, credit rating or liquidity. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than Impax has described. All such factors are difficult to predict and beyond our control. All forward-looking statements included in this document are based upon information available to Impax on the date hereof, and unless legally required, Impax disclaims and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\nParticipants in Solicitation\nImpax, Amneal, Holdco and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Impax's stockholders in respect of the proposed transaction. Information about the directors and executive officers of Impax is set forth in its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on April 5, 2017, and in its Annual Report on Form 10-K for the year ended Dec. 31, 2016. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the proxy statement/prospectus regarding the proposed transaction and other relevant materials filed and to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.\nCONTACTS:\nAmneal\nApurva Saraf\n(631) 742-7674\nImpax\nMark Donohue\n(215) 558-4526\nView original content: http://www.prnewswire.com/news-releases/andrew-s-boyer-joins-amneal-pharmaceuticals-as-executive-vice-president-commercial-operations-300593769.html\nSOURCE Impax Laboratories, Inc.; Amneal Pharmaceuticals LLC", "external_links": ["http://www.impaxlabs.com/", "http://www.amneal.com/", "http://www.prnewswire.com/news-releases/andrew-s-boyer-joins-amneal-pharmaceuticals-as-executive-vice-president-commercial-operations-300593769.html", "http://www.sec.gov/"], "published": "2018-02-06T15:30:00.000+02:00", "crawled": "2018-02-06T16:34:48.067+02:00", "highlightTitle": ""}